Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 15/20 | 0.64 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774495 | 1.00 | LCK (0.64) | LCKCNR2LMNAHTTRAB9A | |
| SCHEMBL3577070 | 0.81 | RAB9A (0.61) | LCKCNR2LMNAHTTRAB9A | |
| SCHEMBL3591075 | 0.80 | CNR2 (0.56) | CNR2LMNAHTTRAB9ANPSR1 | |
| SCHEMBL773488 | 0.80 | LCK (0.82) | LCK | |
| SCHEMBL6057987 | 0.80 | LCK (0.69) | LCKCNR1 | |
| SCHEMBL14503275 | 0.79 | ALDH1A1 (0.56) | CNR2LMNA | |
| SCHEMBL773293 | 0.79 | LCK (0.65) | LCK | |
| SCHEMBL1540000 | 0.79 | LCK (1.00) | LCK | |
| SCHEMBL773594 | 0.79 | LCK (0.85) | LCK | |
| SCHEMBL15891867 | 0.78 | LCK (0.78) | LCKHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| US-20150366972-A1 | METHODS AND MATERIALS FOR THERAPEUTIC DELIVERY | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | LCK 1/4885CNR2 4135/4885LMNA 4599/4885 |
| US-20150366972-A1 | METHODS AND MATERIALS FOR THERAPEUTIC DELIVERY | HTT, HDGF, PAM | LCK 2131/4885CNR2 2986/4885LMNA 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.